But since the vast majority of non-enhancing gliomas IDH wild type in adults are molecular glioblastomas, and that CDKN2A/B homozygous deletion is rare in the WHO grade 2 group (61), we believe that the results at the group level would not differ from what we have presented. The gene discussed is CDKN2A; the disease is glioblastoma.